These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 22621684

  • 1. Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
    Aujla JS.
    Clin Exp Optom; 2012 Sep; 95(5):538-40. PubMed ID: 22621684
    [Abstract] [Full Text] [Related]

  • 2. Response to Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
    O'Shea JG.
    Clin Exp Optom; 2012 Sep; 95(5):541-3. PubMed ID: 22672003
    [No Abstract] [Full Text] [Related]

  • 3. Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab.
    Jiang S, Park C, Barner JC.
    J Clin Pharm Ther; 2014 Jun; 39(3):234-9. PubMed ID: 24635444
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bevacizumab for the treatment of neovascular age-related macular degeneration.
    Pitlick JM, Vecera KF, Barnes KN, Reski JW, Forinash AB.
    Ann Pharmacother; 2012 Feb; 46(2):290-6. PubMed ID: 22274144
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, GEFAL Study Group.
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [Abstract] [Full Text] [Related]

  • 11. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ, Bell CM, Paterson JM, Bronskill SE, Moineddin R, Whitehead M, Gill SS.
    Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Preferred therapies for neovascular age-related macular degeneration.
    Chiang A, Regillo CD.
    Curr Opin Ophthalmol; 2011 May; 22(3):199-204. PubMed ID: 21427571
    [Abstract] [Full Text] [Related]

  • 14. Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned?
    Do DV.
    Ophthalmology; 2013 May; 120(5 Suppl):S8-10. PubMed ID: 23642785
    [Abstract] [Full Text] [Related]

  • 15. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, Bhatia S, Patel P, Nguyen M, Houranieh A.
    Am J Ophthalmol; 2009 Dec; 148(6):875-82.e1. PubMed ID: 19800611
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Can genetic factors predict response to antivascular endothelial growth factor therapy in age-related macular degeneration?
    Micieli JA.
    Can J Ophthalmol; 2011 Dec; 46(6):549-51. PubMed ID: 22153646
    [No Abstract] [Full Text] [Related]

  • 19. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N, Damico L, Shams N, Lowman H, Kim R.
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.